(VIANEWS) – Another day of trading has ended and here’s today’s list of stocks that have had significant trading activity in the US session.

The three biggest winners today are Greenrose Acquisition Corp., Whole Earth Brands, and Entera Bio Ltd..

The three biggest losers today are Fortress Biotech, Canaan, and Marathon.

Winners today

1. Greenrose Acquisition Corp. (GNRS) – 33.33%

Greenrose Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or similar business combination with one or more businesses or entities. The company was incorporated in 2019 and is based in Amityville, New York.

NASDAQ ended the session with Greenrose Acquisition Corp. jumping 33.33% to $0.00 on Monday, following the last session’s upward trend. NASDAQ slid 0.56% to $15,011.35, after two successive sessions in a row of losses, on what was a somewhat down trend trading session today.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 346.23%.

More news about Greenrose Acquisition Corp..

2. Whole Earth Brands (FREEW) – 14.29%

Whole Earth Brands, Inc. operates as a food company worldwide. It operates through two segments, Branded CPG and Flavors & Ingredients. The Branded CPG segment focuses on building a branded portfolio serving consumers seeking zero-calorie, low-calorie, organic, non-GMO, no-sugar added, and plant-based, and Fair Trade spaces in zero/low calorie sweeteners, honey, agave, baking mix, and baking chocolate products. It sells products under the Whole Earth, Pure Via, Wholesome, Swerve, Canderel, and Equal brands. This segment offers various sweetener formulations under each brand to address local consumer preferences and price points. The Flavors & Ingredients segment provides functional ingredients with flavoring enhancement, flavor/aftertaste masking, moisturizing, product mouth feel modification, and skin soothing characteristics. This segment also offers licorice-derived products for use in confectionary, food, beverage, cosmetic, pharmaceutical, personal care, and tobacco products applications. The company was incorporated in 2020 and is based in Chicago, Illinois.

NASDAQ ended the session with Whole Earth Brands jumping 14.29% to $0.08 on Monday, after five consecutive sessions in a row of losses. NASDAQ dropped 0.56% to $15,011.35, after two consecutive sessions in a row of losses, on what was a somewhat down trend trading session today.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -32.35%.

Revenue Growth

Year-on-year quarterly revenue growth declined by 0.6%, now sitting on 538.65M for the twelve trailing months.

More news about Whole Earth Brands.

3. Entera Bio Ltd. (ENTX) – 8.95%

Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, an oral parathyroid hormone product candidate, which is in Phase 2 clinical trials for the treatment of hypoparathyroidism; and EB613 that is in Phase 2 clinical trials for the treatment of osteoporosis. It is also developing EB613 for the treatment of non-union fractures. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.

NASDAQ ended the session with Entera Bio Ltd. rising 8.95% to $0.60 on Monday, following the last session’s upward trend. NASDAQ fell 0.56% to $15,011.35, after two sequential sessions in a row of losses, on what was a somewhat down trend trading session today.

Earnings Per Share

As for profitability, Entera Bio Ltd. has a trailing twelve months EPS of $-0.34.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -96.64%.

Volatility

Entera Bio Ltd.’s last week, last month’s, and last quarter’s current intraday variation average was a negative 2.16%, a negative 0.52%, and a positive 3.64%.

Entera Bio Ltd.’s highest amplitude of average volatility was 6.84% (last week), 4.10% (last month), and 3.64% (last quarter).

Earnings Before Interest, Taxes, Depreciation, and Amortization

Entera Bio Ltd.’s EBITDA is -5.15.

Yearly Top and Bottom Value

Entera Bio Ltd.’s stock is valued at $0.60 at 16:32 EST, way under its 52-week high of $1.48 and way higher than its 52-week low of $0.52.

More news about Entera Bio Ltd..

4. Forte Biosciences (FBRX) – 8.12%

Forte Biosciences Inc. operates as a clinical-stage biopharmaceutical company in the United States. It is developing a live biotherapeutic FB-401 that has completed Phase 1/2a clinical trial to treat inflammatory skin diseases for pediatric atopic dermatitis patients. The company was incorporated in 2007 and is based in Torrance, California.

NASDAQ ended the session with Forte Biosciences rising 8.12% to $0.82 on Monday, after two consecutive sessions in a row of gains. NASDAQ dropped 0.56% to $15,011.35, after two successive sessions in a row of losses, on what was a somewhat down trend exchanging session today.

Earnings Per Share

As for profitability, Forte Biosciences has a trailing twelve months EPS of $-1.2.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -73.23%.

Moving Average

Forte Biosciences ‘s worth is way higher than its 50-day moving average of $0.55 and below its 200-day moving average of $0.84.

Yearly Top and Bottom Value

Forte Biosciences ‘s stock is valued at $0.82 at 16:32 EST, way below its 52-week high of $1.29 and way higher than its 52-week low of $0.38.

More news about Forte Biosciences .

5. HOOKIPA Pharma (HOOK) – 8.01%

HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in Phase I/II clinical trial for the treatment of human papillomavirus 16-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop infectious disease product candidates intended to support functional cures for chronic Hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was incorporated in 2011 and is headquartered in New York, New York.

NASDAQ ended the session with HOOKIPA Pharma jumping 8.01% to $0.81 on Monday, following the last session’s upward trend. NASDAQ slid 0.56% to $15,011.35, after two successive sessions in a row of losses, on what was a somewhat down trend trading session today.

Earnings Per Share

As for profitability, HOOKIPA Pharma has a trailing twelve months EPS of $-0.8.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -66.29%.

Revenue Growth

Year-on-year quarterly revenue growth grew by 207.9%, now sitting on 20.55M for the twelve trailing months.

Moving Average

HOOKIPA Pharma’s value is way above its 50-day moving average of $0.55 and higher than its 200-day moving average of $0.80.

Sales Growth

HOOKIPA Pharma’s sales growth is negative 41.9% for the present quarter and negative 45.3% for the next.

More news about HOOKIPA Pharma.

6. Flux Power Holdings (FLUX) – 7.59%

Flux Power Holdings, Inc., through its subsidiary Flux Power, Inc., designs, develops, manufactures, and sells lithium-ion energy storage solutions for lift trucks, airport ground support equipment, and other industrial and commercial applications in the United States. It offers battery management system (BMS) that provides cell balancing, charging, discharging, monitoring, and communication between the pack and the forklift. The company also provides 24-volt onboard chargers for its Class 3 Walkie LiFT packs; and smart wall mounted chargers to interface with its BMS. The company sells its products directly to small companies and end-users, as well as through original equipment manufacturers, lift equipment dealers, and battery distributors. Flux Power Holdings, Inc. was incorporated in 1998 and is based in Vista, California.

NASDAQ ended the session with Flux Power Holdings rising 7.59% to $4.11 on Monday, after two consecutive sessions in a row of gains. NASDAQ fell 0.56% to $15,011.35, after two sequential sessions in a row of losses, on what was a somewhat negative trend trading session today.

Earnings Per Share

As for profitability, Flux Power Holdings has a trailing twelve months EPS of $-0.42.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -68.51%.

Yearly Top and Bottom Value

Flux Power Holdings’s stock is valued at $4.11 at 16:32 EST, way below its 52-week high of $7.50 and way higher than its 52-week low of $2.97.

Growth Estimates Quarters

The company’s growth estimates for the ongoing quarter and the next is 60% and 66.7%, respectively.

More news about Flux Power Holdings.

7. Farmmi (FAMI) – 6.9%

Farmmi, Inc., together with its subsidiaries, processes and sells agricultural products in China, the United States, Japan, Canada, Europe, Korea, and the Middle East. The company offers shiitake and Mu Er mushrooms; and other edible fungi products, including bamboo fungi, agrocybe aegerila, pleurotus eryngii, grifola frondosa, coprinus comatus, and hericium erinaceus. It also operates Farmmi Jicai, an online store that sells edible fungi products under Forasen and Farmmi Liangpin brands. In addition, the company exports dried whole and sliced shiitake mushrooms, and dried black fungus to Israel. It offers its products to restaurants, cafeterias, and local specialty stores, as well as through distributors. Farmmi, Inc. was incorporated in 2015 and is headquartered in Lishui, China.

NASDAQ ended the session with Farmmi rising 6.9% to $1.24 on Monday while NASDAQ slid 0.56% to $15,011.35.

Earnings Per Share

As for profitability, Farmmi has a trailing twelve months EPS of $34.

PE Ratio

Farmmi has a trailing twelve months price to earnings ratio of 0.04. Meaning, the purchaser of the share is investing $0.04 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 2.64%.

More news about Farmmi.

8. DouYu (DOYU) – 6.55%

DouYu International Holdings Limited, together with its subsidiaries, operates a platform on PC and mobile apps that provides interactive games and entertainment live streaming services in the People's Republic of China. Its platform connects game developers and publishers, professional eSports teams or players and eSports tournament organizers, advertisers, and viewers. The company also sponsors professional players and teams, and organizes eSports tournaments. In addition, it streams other content to include a spectrum of live streaming entertainment options, such as talent shows, music, outdoor, and travel. Further, the company records and offers video clips to allow users to watch replays of selective live streaming content. DouYu International Holdings Limited was founded in 2014 and is headquartered in Wuhan, the People's Republic of China.

NASDAQ ended the session with DouYu jumping 6.55% to $0.95 on Monday, after two successive sessions in a row of gains. NASDAQ dropped 0.56% to $15,011.35, after two sequential sessions in a row of losses, on what was a somewhat down trend exchanging session today.

Earnings Per Share

As for profitability, DouYu has a trailing twelve months EPS of $0.06.

PE Ratio

DouYu has a trailing twelve months price to earnings ratio of 15.83. Meaning, the purchaser of the share is investing $15.83 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 2.08%.

More news about DouYu.

9. Equillium (EQ) – 6.32%

Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. Its primary product candidate is itolizumab, a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase 1b/2 clinical trials for the treatment of acute graft-versus-host disease; and Phase 1 clinical trial for the treatment of asthma and lupus nephritis. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.

NASDAQ ended the session with Equillium jumping 6.32% to $0.72 on Monday, after three successive sessions in a row of gains. NASDAQ dropped 0.56% to $15,011.35, after two consecutive sessions in a row of losses, on what was a somewhat down trend exchanging session today.

Earnings Per Share

As for profitability, Equillium has a trailing twelve months EPS of $-0.22.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -31.45%.

Moving Average

Equillium’s worth is way higher than its 50-day moving average of $0.57 and higher than its 200-day moving average of $0.69.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Equillium’s EBITDA is 6.84.

Yearly Top and Bottom Value

Equillium’s stock is valued at $0.72 at 16:32 EST, way under its 52-week high of $1.35 and way above its 52-week low of $0.45.

More news about Equillium.

10. Enlivex Therapeutics Ltd. (ENLV) – 4.65%

Enlivex Therapeutics Ltd. operates as a clinical stage immunotherapy company. It is developing Allocetra, an off-the-shelf cell therapy designed to reprogram macrophages into homeostatic state. Resetting non-homeostatic macrophages into homeostatic state is critical for immune system rebalancing and resolution of life-threatening conditions. Diseases, such as solid cancers, sepsis, COVID-19, and others reprogram macrophages out of homeostatic state. Its Allocetra has the potential to provide a novel immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as unmet medical needs, as a stand-alone therapy or in combination with therapeutic agents. The company has a research collaboration with Yale Cancer Center for the assessment of Allocetra to enhance the activity of checkpoint inhibitors in solid tumors. Enlivex Therapeutics Ltd. was incorporated in 2005 and is headquartered in Nes Ziona, Israel.

NASDAQ ended the session with Enlivex Therapeutics Ltd. jumping 4.65% to $2.70 on Monday while NASDAQ fell 0.56% to $15,011.35.

Earnings Per Share

As for profitability, Enlivex Therapeutics Ltd. has a trailing twelve months EPS of $-1.47.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -53.23%.

Volume

Today’s last reported volume for Enlivex Therapeutics Ltd. is 167536 which is 190.52% above its average volume of 57666.

Yearly Top and Bottom Value

Enlivex Therapeutics Ltd.’s stock is valued at $2.70 at 16:32 EST, way below its 52-week high of $4.65 and way above its 52-week low of $1.20.

More news about Enlivex Therapeutics Ltd..

Losers Today

1. Fortress Biotech (FBIO) – -22.62%

Fortress Biotech, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino capsules to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris; Targadox for severe acne; Exelderm cream for ringworm and jock itch symptoms; Ceracade for dry skin conditions; Luxamend for dressing and managing wounds; and Accutane capsules for severe recalcitrant nodular acne. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; MB-107 and MB-207 for the treatment of X-linked severe combined immunodeficiency; Cosibelimab for metastatic cancers; CK-101 for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and CEVA101 for the treatment of severe traumatic brain injury in adults and children. The company's early stage product candidates include MB-102 for blastic plasmacytoid dendritic cell neoplasm; MB-101 for glioblastoma; MB-104 for multiple myeloma and light chain amyloidosis; MB-106 for B-cell non-hodgkin lymphoma; MB-103 for GBM & metastatic breast cancer to brain; MB-108; MB-105 for prostate and pancreatic cancers; and BAER-101. Its preclinical product candidates comprise AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; ConVax; and ONCOlogues, and oligonucleotide platform. It has collaboration arrangements with universities, research institutes, and pharmaceutical companies. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in New York, New York.

NASDAQ ended the session with Fortress Biotech dropping 22.62% to $3.01 on Monday, following the last session’s downward trend. NASDAQ fell 0.56% to $15,011.35, after two successive sessions in a row of losses, on what was a somewhat down trend trading session today.

Earnings Per Share

As for profitability, Fortress Biotech has a trailing twelve months EPS of $-11.34.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -414.52%.

More news about Fortress Biotech.

2. Canaan (CAN) – -17.79%

Canaan Inc. engages in the research, design, and sale of integrated circuit (IC) final mining equipment products by integrating IC products for bitcoin mining and related components in the People's Republic of China. It is also involved in the assembly and distribution of mining equipment and spare parts. The company has operations in the United States, Australia, Kazakhstan, Hong Kong, Canada, Mainland China, Thailand, Sweden, and internationally. Canaan Inc. was founded in 2013 and is based in Singapore.

NASDAQ ended the session with Canaan dropping 17.79% to $2.31 on Monday, after two successive sessions in a row of losses. NASDAQ slid 0.56% to $15,011.35, after two successive sessions in a row of losses, on what was a somewhat negative trend trading session today.

Earnings Per Share

As for profitability, Canaan has a trailing twelve months EPS of $-0.47.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -53.23%.

Growth Estimates Quarters

The company’s growth estimates for the present quarter and the next is 34.6% and 75%, respectively.

Volatility

Canaan’s last week, last month’s, and last quarter’s current intraday variation average was a negative 8.63%, a positive 2.24%, and a positive 5.79%.

Canaan’s highest amplitude of average volatility was 11.27% (last week), 10.14% (last month), and 5.79% (last quarter).

More news about Canaan.

3. Marathon (MARA) – -16.44%

Marathon Digital Holdings, Inc. operates as a digital asset technology company that mines digital assets with a focus on the blockchain ecosystem and the generation of digital assets in United States. The company was formerly known as Marathon Patent Group, Inc. and changed its name to Marathon Digital Holdings, Inc. in February 2021. Marathon Digital Holdings, Inc. was incorporated in 2010 and is headquartered in Fort Lauderdale, Florida.

NASDAQ ended the session with Marathon dropping 16.44% to $23.49 on Monday, after two successive sessions in a row of losses. NASDAQ slid 0.56% to $15,011.35, after two sequential sessions in a row of losses, on what was a somewhat down trend exchanging session today.

Earnings Per Share

As for profitability, Marathon has a trailing twelve months EPS of $-3.08.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -42.13%.

Volatility

Marathon’s last week, last month’s, and last quarter’s current intraday variation average was a negative 3.51%, a positive 2.91%, and a positive 5.65%.

Marathon’s highest amplitude of average volatility was 11.60% (last week), 7.64% (last month), and 5.65% (last quarter).

More news about Marathon.

4. Eiger BioPharmaceuticals (EIGR) – -15.66%

Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia. The company was founded in 2008 and is headquartered in Palo Alto, California.

NASDAQ ended the session with Eiger BioPharmaceuticals dropping 15.66% to $0.22 on Monday, following the last session’s downward trend. NASDAQ slid 0.56% to $15,011.35, after two successive sessions in a row of losses, on what was a somewhat down trend exchanging session today.

Earnings Per Share

As for profitability, Eiger BioPharmaceuticals has a trailing twelve months EPS of $-1.95.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -225.93%.

Moving Average

Eiger BioPharmaceuticals’s value is way under its 50-day moving average of $0.30 and way below its 200-day moving average of $0.68.

Growth Estimates Quarters

The company’s growth estimates for the current quarter and the next is 56.1% and 65.4%, respectively.

More news about Eiger BioPharmaceuticals.

5. Riot Blockchain (RIOT) – -12.1%

Riot Platforms, Inc., together with its subsidiaries, operates as a bitcoin mining company in North America. It operates through Bitcoin Mining, Data Center Hosting, and Engineering segments. The company also provides co-location services for institutional-scale bitcoin mining companies; and critical infrastructure and workforce for institutional-scale miners to deploy and operate their miners. In addition, it engages in the design and manufacturing of power distribution equipment and custom engineered electrical products; electricity distribution product design, manufacture, and installation services primarily focused on large-scale commercial and governmental customers, as well as a range of markets, including data center, power generation, utility, water, industrial, and alternative energy; operation of data centers; and maintenance/management of computing capacity. The company was formerly known as Riot Blockchain, Inc. Riot Platforms, Inc. was incorporated in 1998 and is based in Castle Rock, Colorado.

NASDAQ ended the session with Riot Blockchain sliding 12.1% to $15.47 on Monday, after two successive sessions in a row of losses. NASDAQ slid 0.56% to $15,011.35, after two sequential sessions in a row of losses, on what was a somewhat down trend exchanging session today.

Earnings Per Share

As for profitability, Riot Blockchain has a trailing twelve months EPS of $-1.8.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -21.88%.

Volatility

Riot Blockchain’s last week, last month’s, and last quarter’s current intraday variation average was a negative 3.68%, a positive 0.60%, and a positive 4.47%.

Riot Blockchain’s highest amplitude of average volatility was 7.34% (last week), 4.77% (last month), and 4.47% (last quarter).

More news about Riot Blockchain.

6. Future FinTech Group (FTFT) – -9.85%

Future FinTech Group Inc., through its subsidiaries, operates a real-name block chain e-commerce platform that integrates block chain and internet technology in People's Republic of China. It operates through CCM Shopping Mall Membership, Sales of Goods, and Others segments. The company offers Chain Cloud Mall (CCM), an enterprise customer interactive and comprehensive shopping and sales service platform; NONOGIRL, a cross-border e-commerce platform; and DCON, a block chain-based application incubator and a digital payment system. It also engages in the development of block chain-based e-commerce and financial technology; and provides technical services and support for real name and blockchain based assets. The company was formerly known as SkyPeople Fruit Juice, Inc. and changed its name to Future FinTech Group Inc. in June 2017. Future FinTech Group Inc. is headquartered in Beijing, the People's Republic of China.

NASDAQ ended the session with Future FinTech Group sliding 9.85% to $1.83 on Monday while NASDAQ slid 0.56% to $15,011.35.

Earnings Per Share

As for profitability, Future FinTech Group has a trailing twelve months EPS of $-0.8.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -18.54%.

Moving Average

Future FinTech Group’s worth is way above its 50-day moving average of $0.92 and way above its 200-day moving average of $1.19.

Volume

Today’s last reported volume for Future FinTech Group is 928838 which is 827.59% above its average volume of 100134.

Yearly Top and Bottom Value

Future FinTech Group’s stock is valued at $1.83 at 16:32 EST, way below its 52-week high of $2.60 and way higher than its 52-week low of $0.37.

More news about Future FinTech Group.

7. Bionano Genomics (BNGO) – -8.25%

Bionano Genomics, Inc. provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight. The company also provides Saphyr and Bionano compute servers; and NxClinical software, which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; EpiPanelDx PLUS, a genetic testing panel for patients who have experienced seizures, infantile spasms, encephalopathy, or febrile seizures; PGx test, which identifies over 60 alleles in 11 genes. The company was founded in 2003 and is headquartered in San Diego, California.

NASDAQ ended the session with Bionano Genomics dropping 8.25% to $1.89 on Monday while NASDAQ slid 0.56% to $15,011.35.

Earnings Per Share

As for profitability, Bionano Genomics has a trailing twelve months EPS of $-7.17.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -113.43%.

Volume

Today’s last reported volume for Bionano Genomics is 2496580 which is 80.01% above its average volume of 1386880.

Revenue Growth

Year-on-year quarterly revenue growth grew by 29%, now sitting on 33.61M for the twelve trailing months.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Bionano Genomics’s EBITDA is 0.33.

Growth Estimates Quarters

The company’s growth estimates for the ongoing quarter and the next is 33.1% and 37.5%, respectively.

More news about Bionano Genomics.

8. Hoth Therapeutics (HOTH) – -7.69%

Hoth Therapeutics, Inc., a biopharmaceutical company, focuses on developing therapies for dermatological disorders. The company focuses on therapies for patients suffering from indications, including eczema, chronic wounds, psoriasis, asthma, and acne. Its pipeline portfolio includes HT-001, a topical formulation for the treatment of mild to moderate rash and skin disorders associated with initial and repeat courses of tyrosine kinase inhibitor/epidermal growth factor receptor (EGFR) inhibitor therapy; HT-002 to treat illness associated with SARS-CoV-2 infection; HT-003D for the topical treatment in acne and psoriasis applications; HT-003IB to treat inflammatory bowel diseases; HT-004 for the treatment of asthma, atopic dermatitis, and other allergic diseases; HT-005 Z-PODS to treat cutaneous lupus erythematosus; HT-006 for treatment of multiple bacterial pathogens. The company has license agreements with the George Washington University; the University of Maryland; Isoprene Pharmaceuticals, Inc.; the North Carolina State University; Chelexa BioSciences, Inc.; and the University of Cincinnati. It also has a partnership agreement with Zylö Therapeutics Inc. co-develop a new topical treatment for patients with Cutaneous Lupus Erythematosu, a chronic autoimmune disease that affects the skin and is associated with a significant burden on patient quality of life; and research collaboration agreement with Weill Cornell Medicine to continue the advancement of HT-003 for acne treatment research. Hoth Therapeutics, Inc. was incorporated in 2017 and is headquartered in New York, New York.

NASDAQ ended the session with Hoth Therapeutics sliding 7.69% to $1.44 on Monday while NASDAQ slid 0.56% to $15,011.35.

Earnings Per Share

As for profitability, Hoth Therapeutics has a trailing twelve months EPS of $-4.71.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -100.65%.

More news about Hoth Therapeutics.

9. Hall of Fame Resort & Entertainment Company (HOFV) – -7.67%

Hall of Fame Resort & Entertainment Company, a resort and entertainment company, doing business as the Pro Football Hall of Fame. It owns the premier sports, entertainment, and media enterprise surrounding the Pro Football Hall of Fame in Canton, Ohio. The company was founded in 2015 and is headquartered in Canton, Ohio.

NASDAQ ended the session with Hall of Fame Resort & Entertainment Company dropping 7.67% to $3.25 on Monday, following the last session’s downward trend. NASDAQ fell 0.56% to $15,011.35, after two sequential sessions in a row of losses, on what was a somewhat bearish trend exchanging session today.

Earnings Per Share

As for profitability, Hall of Fame Resort & Entertainment Company has a trailing twelve months EPS of $-12.21.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -38.38%.

Growth Estimates Quarters

The company’s growth estimates for the ongoing quarter is 25.5% and a drop 3.7% for the next.

Revenue Growth

Year-on-year quarterly revenue growth grew by 7.6%, now sitting on 21.05M for the twelve trailing months.

More news about Hall of Fame Resort & Entertainment Company.

10. Arcimoto (FUV) – -7.27%

Arcimoto, Inc. designs, develops, manufactures, sells, and rents three-wheeled electric vehicles in the United States. Its flagship product is the Fun Utility Vehicle (FUV) that delivers a thrilling ride experience comfort for two passengers with cargo, parking, and operation. The company's products also comprise Rapid Responder designed to perform emergency, security, and law enforcement services; Deliverator, an electric last-mile delivery solution to get goods where they need to go; Cameo, an FUV equipped with a rear-facing rear seat and a modified roof built for on-road filming; and Arcimoto Roadster, an unparalleled pure-electric on-road thrill machine. The company was formerly known as WTP Incorporated and changed its name to Arcimoto, Inc. in December 2011. Arcimoto, Inc. was incorporated in 2007 and is headquartered in Eugene, Oregon.

NASDAQ ended the session with Arcimoto falling 7.27% to $0.86 on Monday, following the last session’s downward trend. NASDAQ dropped 0.56% to $15,011.35, after two consecutive sessions in a row of losses, on what was a somewhat down trend trading session today.

Earnings Per Share

As for profitability, Arcimoto has a trailing twelve months EPS of $-15.61.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -165.43%.

Revenue Growth

Year-on-year quarterly revenue growth grew by 17.4%, now sitting on 7.52M for the twelve trailing months.

Volume

Today’s last reported volume for Arcimoto is 145692 which is 3.17% below its average volume of 150477.

Yearly Top and Bottom Value

Arcimoto’s stock is valued at $0.86 at 16:32 EST, way under its 52-week high of $6.14 and way higher than its 52-week low of $0.52.

Moving Average

Arcimoto’s value is way above its 50-day moving average of $0.71 and way under its 200-day moving average of $1.17.

More news about Arcimoto.

Stay up to date with our winners and losers daily report